Preclinical studies have demonstrated that ASO therapy significantly ameliorates seizures and mortality in DS and has improved behavioral outcomes in treated mice, with brain NaV1.1 levels increased to become comparable to wild type mice [15]. Here, SCN1A is linked to Dravet syndrome.